Should I give Lantus (insulin glargine) as 52 units once daily or 25 units twice daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lantus Should Be Given as 52 Units Once Daily

For Lantus (insulin glargine), you should administer 52 units once daily rather than splitting to 25 units twice daily. The FDA-approved dosing for Lantus is once-daily administration, and this is the standard of care supported by both the drug label and current guidelines 1.

Rationale for Once-Daily Dosing

Lantus is specifically designed as a long-acting basal insulin with a relatively constant glucose-lowering profile over 24 hours that permits once-daily dosing 1. The FDA label explicitly states that "LANTUS should be administered subcutaneously once a day at the same time every day" 1.

Key pharmacologic principle: Lantus exhibits a peakless, 24-hour duration of action when given as a single daily injection, which is its intended therapeutic profile 1.

When Converting from NPH to Lantus

If this patient is being converted from twice-daily NPH insulin, the FDA label provides specific guidance: when transferring from twice-daily NPH to once-daily Lantus, use 80% of the total NPH dose 1. This dose reduction (from 50 units NPH total to approximately 40 units Lantus) helps lower the likelihood of hypoglycemia.

Your proposed 52 units once daily would represent the full NPH dose without reduction, which may increase hypoglycemia risk.

Evidence on Twice-Daily Lantus Dosing

While research exists showing twice-daily Lantus can be used in specific clinical scenarios 2, 3, these are exceptions to standard practice, not the rule:

  • Twice-daily dosing has been studied primarily in Type 1 diabetes patients experiencing late-afternoon glucose rises or morning hypoglycemia despite dose titration 3
  • One small study showed twice-daily dosing reduced predose hyperglycemia in critically ill patients 4
  • These represent salvage strategies for patients failing standard once-daily dosing 2, 5

Clinical Algorithm

Follow this approach:

  1. Start with once-daily Lantus at 52 units (or 80% of total NPH dose if converting from twice-daily NPH = ~40 units)
  2. Administer at the same time each day - patient can choose morning or evening based on convenience 1
  3. Monitor fasting plasma glucose and titrate by 2 units every 3 days to reach fasting glucose goal without hypoglycemia 6
  4. Only consider twice-daily dosing if:
    • Patient experiences recurrent morning hypoglycemia despite dose reduction
    • Late afternoon/evening hyperglycemia occurs with good morning control
    • Patient has documented loss of glycemic control in the 18-24 hour window after injection

Important Caveats

  • Do not split Lantus doses without documented failure of once-daily dosing - this increases injection burden and deviates from FDA-approved use
  • The 2025 ADA guidelines recommend basal insulin analogs be dosed once daily per their pharmacokinetic profiles 6
  • Twice-daily dosing increases cost and patient burden without proven superiority in most patients 2
  • If glycemic control is inadequate on optimized once-daily basal insulin, consider adding GLP-1 RA or prandial insulin rather than splitting basal doses 6

Bottom line: Use 52 units once daily as the standard approach. Reserve twice-daily dosing only for patients who fail once-daily optimization despite appropriate titration.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.